Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer
A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer
Cervical Cancer
DRUG: niraparib combined with brivanib|DRUG: niraparib combined with toripalimab
ORR, Objective To evaluate the objective response rate (CR + PR) of ZL-2306 (niraparib) combined with brivanib or toripalimab in patients with relapsed and persistent cervical cancer., 6 months
PFS, progression-free survival, 6 months|DCR, evaluate the safety of combined application of ZL-2306 (niraparib) combined with brivanib or toripalimabï¼Œ disease control rate, 6 months
A prospective, open-ended, single-arm, phase II clinical study.Patients are with metastatic, recurrent, persistent cervical cancer (squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma) To observe the efficacy and safety of ZL-2306 (Niraparib) combined with Brivanib or Toripalimab in patients with metastatic, recurrent and persistent cervical cancer, and to explore the biomarkers of effectiveness.